• Copanlisib comes as a powder for reconstitution which is given as an injection directly into a vein through a needle or a catheter.
• 4.4 ml of 0.9% sodium chloride should be added to the vial and the vial should be shaken for 30 seconds to dissolve the powder.
• The vial can be shaken again gently if any undissolved substances are seen.
• The solution should be further diluted in 100 ml of 0.9% sodium chloride and infused over 1 hour.
• Before administration of the infusion, it is necessary to inspect the solution for the presence of any particulate matter or discoloration. If present, the solution should be discarded.
• The infusion is administered on an intermittent schedule on days 1, 8, 15 in a treatment cycle of 28 days.
• The treatment should be continued until disease progression or any unacceptable toxicity.
• A reduced dosage of 45 mg or 30 mg may be required if certain side effects occur during treatment or if it is taken with certain drugs.
• Patients with allergy to copanlisib
• Pregnancy and breastfeeding
• Children below 18 years of age
• With drugs that strongly induce or inhibit the CYP3A enzyme. Some of these are mentioned in the drug interactions below
• 4.4 ml of 0.9% sodium chloride should be added to the vial and the vial should be shaken for 30 seconds to dissolve the powder.
• The vial can be shaken again gently if any undissolved substances are seen.
• The solution should be further diluted in 100 ml of 0.9% sodium chloride and infused over 1 hour.
• Before administration of the infusion, it is necessary to inspect the solution for the presence of any particulate matter or discoloration. If present, the solution should be discarded.
Dosage & When it is to be taken
• The recommended adult dose of copanlisib is 60 mg which is administered as an intravenous infusion over 1 hour.• The infusion is administered on an intermittent schedule on days 1, 8, 15 in a treatment cycle of 28 days.
• The treatment should be continued until disease progression or any unacceptable toxicity.
• A reduced dosage of 45 mg or 30 mg may be required if certain side effects occur during treatment or if it is taken with certain drugs.
When it is not to be taken (Contraindications)
Copanlisib should not be used in-• Patients with allergy to copanlisib
• Pregnancy and breastfeeding
• Children below 18 years of age
• With drugs that strongly induce or inhibit the CYP3A enzyme. Some of these are mentioned in the drug interactions below
